Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Regulatory Update and Interim Phase 1/2 Data Update for LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Call Transcript
Company Participants
Louis Tamayo – CFO & Principal Accounting Officer
R. Townsend – CEO & Director
Sandi Tai – Chief Development Officer
Eric Adler – Chief Medical Officer & Head of Research
Conference Call Participants
Tessa Romero – JPMorgan Chase & Co, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Lili Nsongo – Leerink Partners LLC, Research Division
Leland Gershell – Oppenheimer & Co. Inc., Research Division
Mitchell Kapoor – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, and welcome to the Lexeo Therapeutics webcast presentation on LX2006 for the treatment of Friedreich’s ataxia cardiomyopathy. As a reminder, this call is being recorded today, October 7, 2025.
I would now like to turn the conference over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead.
Louis Tamayo
CFO & Principal Accounting Officer
Earlier today, we released the regulatory update on our discussions to date with the FDA regarding a potential accelerated approval pathway for LX2006 for the treatment of Friedreich’s ataxia cardiomyopathy alongside new interim clinical data from 2 ongoing Phase I/II clinical studies. The press release outlining these updates is available on our website lexeotx.com, and an 8-K was filed with the SEC this morning.
Joining us on today’s call will be Nolan Townsend, Chief Executive Officer; and Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics; Dr. Eric Adler, Chief Medical Officer and Head of Research; and Dr. Manny Otero, Chief Technical Officer, will also be available for Q&A following the call.
Before we begin, I would like to remind you that this call will contain forward-looking statements regarding Lexeo’s future expectations, plans and prospects which constitute forward-looking statements
Credit: Source link
